Abstract
Glycoconjugate vaccines against bacterial infection have been in clinical use for decades and achieved a great success. To provide the broad protection from different serotype of bacteria, polyvalent vaccines were also generated from various bacterial capsular polysaccharides. With the outstanding achievement in glycoconjugate vaccines against bacteria, recent studies tried to develop glycoconjugate vaccines against cancer by the tumor-associated carbohydrate antigens (TACAs). This article will discuss the history of carbohydrate-based vaccine development, the mechanism of the carbohydrate-based vaccines, the FDA-approved glycoconjugates vaccines against bacteria, and also the recent design of the TACA-based vaccines and their possible mechanism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
